Short answer
RIGEL PHARMACEUTICALS INC (RIGL) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 provides no operating or financial results; substantive information appears limited to the accompanying exhibit.
RIGEL PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 provides no operating or financial results; substantive information appears limited to the accompanying exhibit
- Disclosure is furnished rather than filed, limiting liability under Exchange Act Section 18 and Securities Act Sections 11 and 12(a)(2)
- Information is excluded from incorporation by reference into Rigel’s other SEC filings
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $78.7M, with product sales $67.0M up 14%; TAVALISSE led growth at $47.4M, up 18%
- Net income $17.3M versus $59.6M, reflecting prior-year $40.0M non-cash Lilly collaboration revenue
- VEPPANU license adds a commercial breast-cancer product; $70.0M upfront payment and U.S. availability expected mid-August
- 2026 revenue guidance increased to approximately $285-$295M, excluding VEPPANU sales
- Cash declined to $95.3M from $155.0M, while R289 Phase 1b enrollment and Phase 2 dose selection remain targeted for second-half 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RIGEL PHARMACEUTICALS INC 8-K filings
Get the next RIGL 8-K as it lands
Follow RIGL for push alerts, or ask the research agent what this filing means.